Is Buying 52-Week Stock Like Sophiris Bio, Inc. (SPHS) a Winning Strategy?

May 17, 2018 - By Hannah Black

Sophiris Bio, Inc. (NASDAQ:SPHS) Logo

Investors sentiment increased to 2.8 in 2017 Q4. Its up 2.16, from 0.64 in 2017Q3. It is positive, as 2 investors sold Sophiris Bio, Inc. shares while 3 reduced holdings. 8 funds opened positions while 6 raised stakes. 1.87 million shares or 14.89% more from 1.63 million shares in 2017Q3 were reported.
Two Sigma Securities Ltd Liability Corp invested in 0% or 16,333 shares. Geode Mngmt Limited Liability Com stated it has 19,042 shares. Sabby Management Ltd Limited Liability Company has invested 0.01% in Sophiris Bio, Inc. (NASDAQ:SPHS). Moreover, Northwestern Mutual Wealth Mgmt has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 400 shares. Financial Bank Of America De accumulated 3,338 shares. National Bank & Trust Of New York Mellon invested in 23,656 shares. Blackrock Inc holds 0% or 79,047 shares in its portfolio. Vanguard Gp Inc holds 784,834 shares. Millennium Limited Liability stated it has 199,705 shares or 0% of all its holdings. Edge Wealth Lc holds 2,000 shares. Citadel holds 0% or 21,608 shares in its portfolio. Morgan Stanley invested in 0% or 5,000 shares. Virtu Ltd Limited Liability Company owns 169,790 shares for 0.02% of their portfolio. Wells Fargo Company Mn owns 1,800 shares or 0% of their US portfolio. Susquehanna Intll Group Llp invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS).

The stock of Sophiris Bio, Inc. (NASDAQ:SPHS) hit a new 52-week high and has $3.53 target or 5.00 % above today’s $3.36 share price. The 6 months bullish chart indicates low risk for the $93.88M company. The 1-year high was reported on May, 17 by Barchart.com. If the $3.53 price target is reached, the company will be worth $4.69 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 4.27% or $0.15 during the last trading session, reaching $3.36. About 599,584 shares traded or 131.38% up from the average. Sophiris Bio, Inc. (NASDAQ:SPHS) has declined 26.06% since May 17, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Analysts await Sophiris Bio, Inc. (NASDAQ:SPHS) to report earnings on May, 21. They expect $-0.12 EPS, down 33.33 % or $0.03 from last year’s $-0.09 per share. After $-0.11 actual EPS reported by Sophiris Bio, Inc. for the previous quarter, Wall Street now forecasts 9.09 % negative EPS growth.

More recent Sophiris Bio, Inc. (NASDAQ:SPHS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” on May 16, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018. Benzinga.com‘s news article titled: “45 Biggest Movers From Yesterday” with publication date: May 16, 2018 was also an interesting one.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $93.88 million. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

Sophiris Bio, Inc. (NASDAQ:SPHS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: